PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007
Open Access
- 30 April 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (12) , 4368-4376
Abstract
Background: Prostate-specific membrane antigen (PSMA)-directed positron emission tomography/computed tomography (PET/CT) has emerged as a highly accurate imaging modality for detecting tumor lesions in patients with biochemical recurrence (BCR) of prostate cancer (PC). While detection rates of lesions suspicious for PC relapse are known to increase with rising prostate-specific antigen (PSA) levels, data on the efficacy of PSMA PET/CT at very low PSA values (≤ 0.2 ng/mL) remain limited. Methods: In this multicenter study, we analyzed 321 patients with BCR and a PSA value ≤ 0.2 ng/mL across five German academic centers, using three different PSMA-targeted radiotracers: [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007 and analyzed the detection rates and potential predictive parameters. Results: The overall pooled detection rate was 29.6%. No statistically significant differences in detection rates were observed between the three radiotracers ([68Ga]Ga-PSMA-11 29.4% vs. [68Ga]Ga-PSMA I&T, 22.5% vs. [18F]PSMA-1007 32.4%, p ≥ 0.314). Detection rates were significantly higher in patients with a PSA level > 0.15 ng/mL (p = 0.029, φ = 0.122), in those with an initial Gleason score > 7 (p = 0.018, φ = 0.141) and in those receiving androgen deprivation therapy (p = 0.031, φ = 0.120). Conclusion: All three radiotracers demonstrated comparable diagnostic performance, with no significant superiority observed between the 68Ga- and 18F-labeled tracers in the patient sample investigated (overall pooled detection rate: 29.6%). This positivity rate can serve as an expectation horizon for both the attending physician and the patient in the case of low PSA values. Further studies with larger cohorts, preferably conducted in a prospective setting, are needed to confirm and expand upon our findings.Keywords
Funding Information
- Universität des Saarlandes
This publication has 33 references indexed in Scilit:
- The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/mlEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2023
- [89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimatesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)European Journal of Nuclear Medicine and Molecular Imaging, 2021
- Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CCEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissuesUrologic Oncology: Seminars and Original Investigations, 1995